Alcon Inc.
ALCCHAlcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.
- Sector
- Medical Devices & Diagnostics
- Sub-sector
- Dental, Vision & Aesthetic Medicine
- Listing
- ALC
- Country
- CH
EV / LTM Revenue
Annual financials & analyst forecasts
| $M | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | CY2026E | CY2027E |
|---|---|---|---|---|---|---|---|
| Revenue YoY | — | 5% | 8% | 5% | 5% | 5% | 6% |
| Revenue | $8.29B | $8.72B | $9.46B | $9.91B | $10.40B | $10.96B | $11.63B |
| Gross Profit | $4.65B | $4.75B | $5.25B | $5.51B | $5.70B | — | — |
| Gross Profit Margin | 56.1% | 54.5% | 55.5% | 55.6% | 54.8% | — | — |
| EBITDA | $1.73B | $1.78B | $2.24B | $2.54B | $2.57B | $2.98B | $3.16B |
| EBITDA Margin | 20.9% | 20.4% | 23.7% | 25.6% | 24.7% | 27.2% | 27.2% |
| EBIT | $580M | $672M | $1.04B | $1.41B | $1.36B | $2.09B | $2.22B |
| Net Income | $376M | $335M | $974M | $1.02B | $980M | $1.70B | $1.94B |
| Free Cash Flow | $165M | $472M | $532M | $1.53B | $1.61B | — | — |
| FCF Margin | 2.0% | 5.4% | 5.6% | 15.5% | 15.5% | — | — |
| Short-Term Debt | $107M | $97M | $63M | $101M | $575M | — | — |
| Long-Term Debt | $3.97B | $4.54B | $4.68B | $4.54B | $4.16B | — | — |
| Cash & Cash Equivalents | $1.57B | $980M | $1.09B | $1.68B | $1.53B | — | — |
| Net Debt | $2.50B | $3.66B | $3.65B | $2.96B | $3.21B | — | — |
| Net Debt / EBITDA | 1.4x | 2.1x | 1.6x | 1.2x | 1.2x | — | — |
| Rule of 40 | — | 10.6% | 14.1% | 20.3% | 20.4% | — | — |